Evidence map›Paper›PMID 40898765›Full record

ArticleClinical and translational medicine2025

PCDHGB7 inhibits the progression of triple-negative breast cancer by suppressing XRCC5/MYC-mediated ribosome biogenesis.

Ming Shan, Hongjie Bi, Hua Sun, Yixin Li, Zhiqi Li, Ziyuan Wang, Jianguo Dong, Shengbo Sang, Lili Ren, Yuguang Ye and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ming ShanDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Hongjie BiDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Hua SunDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Yixin LiDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Zhiqi LiDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Ziyuan WangDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Jianguo DongDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Shengbo SangDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Lili RenDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Yuguang YeDepartment of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China.
Tianzhen WangDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Siniša VolarevićDepartment of Molecular Medicine and Biotechnology, University of Rijeka Faculty of Medicine, Rijeka, Croatia.
Rui SuDepartment of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, California, USA.
Lei ZhangDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Minghui ZhangDepartment of Oncology, Chifeng Municipal Hospital, Chifeng, China.
Yan HeDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Guoqiang ZhangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Jing LiDepartment of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China.
Xiaobo LiDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.ORCID https://orcid.org/0000-0003-1037-3903

Funding

Beijing Innovative Medicine Development Foundation KC2022-JX-0123-03Beijing Medical Award Foundation YXJL-2023-0460-0200Chinese Foundation for Primary Health Care cphcf-2023-018Haiyan Foundation of Harbin Medical University Cancer Hospital JJQN2022-09Haiyan Foundation of Harbin Medical University Cancer Hospital JJZD2024-02HMU Marshal Initiative Funding HMUMIF-21001National Natural Science Foundation of China 82273364National Natural Science Foundation of China 82300223Natural Science Foundation of Inner Mongolia Autonomous Region of China No. 2024MS08043Science and Technology Program of the Joint Fund of Scientific Research for the Public Hospitals of Inner Mongolia Academy of Medical Sciences 2023GLLH0315The "Wu Jieping" Foundation for breast cancer treatment 320.6750.2022-19-106
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40898765
PMCPMC12405659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.